The All India Institute of Medical Sciences (AIIMS) Bhopal has signed a Memorandum of Understanding (MoU) with the Council of Scientific and Industrial Research and the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, to enhance diagnostic capabilities and research initiatives for sickle cell disease and related genetic disorders. This collaboration marks a significant milestone in addressing the challenges of sickle cell disease, particularly in central India.

Prof. (Dr.) Ajai Singh, Executive Director of AIIMS Bhopal, emphasized the importance of this partnership, stating, "Our collaboration with CSIR-CCMB is a significant step towards enhancing diagnostic capabilities for sickle cell disease.

The introduction of this PCR-based test will enable us to offer accurate diagnoses, especially in underserved communities, thereby significantly improving patient care." He further noted that the test is currently in the initial validation phase and will be compared with other government-approved tests.

A key aspect of this partnership is the implementation of a molecular PCR-based diagnostic test developed by CSIR-CCMB, which will be operational at AIIMS Bhopal. This advanced diagnostic tool aims to provide opportunities for rapid and accurate diagnoses for patients, leading to improved management of sickle cell disease.

Dr. Giriraj Chandak, Mission Lead of the Sickle Cell Anemia Mission at CSIR-CCMB, remarked, "This MoU is an important milestone in our mission to bring advances in science to those who need it most. Through this partnership, the PCR-based test we have developed can now benefit countless patients, advancing diagnostic and research capabilities in sickle cell disease."

Beyond the implementation of the PCR-based test, this collaboration will foster joint research projects focused on sickle cell disease and genetic health. The partnership aims to promote advancements in genetic research, enhance clinical understanding, and contribute meaningfully to public health.